Front Cardiovasc Med. 2025 Jul 17;12:1563068. doi: 10.3389/fcvm.2025.1563068. eCollection 2025.
ABSTRACT
BACKGROUND: Galectin-3 is a well-established biomarker on the predictor of cardiovascular events in patients with heart failure. Its pathophysiologic association with inflammation, cell proliferation, and fibrogenesis may implicate serum galectin-3 as a predictor of clinical outcomes in coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). The aim of this study was to examine the prognostic value of the galectin-3 level in patients with CAD who underwent PCI with DES.
METHODS: A total of 939 patients undergoing successful PCI with DES were consecutively enrolled between January 2007 and December 2009. The serum galectin-3 level was measured, classified into two groups according to the median galectin-3 level (9.52 ng/ml, interquartile range 7.31-12.81), and compared with the composite of all-cause mortality, non-fatal myocardial infarction (MI), and stroke.
RESULTS: The median follow-up duration was 997 days (interquartile range 766-1,264 days). The high galectin-3 group had a significantly higher incidence of all-cause mortality, cardiac mortality, and composite of all-cause mortality, non-fatal MI, and stroke. High galectin-3 was a significant independent predictor of the composite of all-cause mortality, non-fatal MI, and stroke (adjusted hazard ratio 1.670, 95% confidence interval 1.014-2.751, p = 0.044). The addition of the serum galectin-3 level to the conventional clinical risk model improves the model discrimination (C-statistic = 0.694-0.786, p for difference < 0.01), reclassification [continuous net classification improvement (0.297, p < 0.01) and integrated discrimination improvement (0.064, p < 0.01)].
CONCLUSION: Our data suggest that serum galectin-3 is an independent predictor of cardiovascular events in patients undergoing PCI with DES.
PMID:40747494 | PMC:PMC12310497 | DOI:10.3389/fcvm.2025.1563068
